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Introduction: 18F-fluorodeoxyglucose positron emission tomogra-
phy/computed tomography (PET/CT) may play an important role in 
staging patients with potentially resectable esophageal cancer but its 
impact on clinical management remains unclear.
Methods: In a multicenter prospective cohort study of patients with 
potentially resectable esophageal cancer, we compared stage of dis-
ease based on PET/CT with the stage based on conventional staging 
performed before PET/CT (American Joint Committee on Cancer, 
6th edition). The primary outcome was the proportion of patients 
with a clinically important change in stage, based on PET/CT find-
ings. We used health administrative databases to track health services 
use and mortality after the index PET/CT scan.
Results: Four hundred ninety-one patients who received a PET/CT 
scan for staging of potentially resectable esophageal cancer were 
included in the study cohort. PET/CT led to clinically important 
changes in stage for a total of 188 patients (24.0%): 107 patients 
(21.8%) were upstaged and 11 patients (2.2%) were downstaged. 
Results of PET/CT were associated with differences in actual man-
agement. At the 6-month follow-up, use of surgery was greater in 
patients with M0 disease (54.4%) compared with those with M1a 
(25.0%; p < 0.001) or M1b (7.3%; p < 0.001) disease based on PET/
CT. The overall cohort had a median survival of 603 days, and higher 
stage of disease on PET/CT (i.e., M stage) was associated with 
shorter survival (p < 0.001).
Conclusions: PET/CT identifies disease not otherwise detected on 
conventional staging and results in clinically important changes 
in stage for an appreciable number of patients with potentially 
resectable esophageal cancer and can make important contributions 
to the management of these patients.
Key Words: Esophageal cancer, Positron emission tomography, 
Staging, Health services research.
(J Thorac Oncol. 2013;8: 1563–1569)
Curative therapy for esophageal cancer can include surgi-cal resection, with or without neoadjuvant chemoradiation 
therapy, or chemoradiation therapy alone. Each of these treat-
ment modalities is associated with substantial morbidity and car-
ries a risk of important complications, including death. The risks 
of aggressive therapies with curative intent would not be worth 
incurring for patients who harbor distant metastatic disease. 
Therefore, accurate staging of patients before curative therapy is 
important to ensure that these intensive therapies are directed to 
patients for whom the benefits of treatment outweigh the harms.
Several studies have evaluated the diagnostic perfor-
mance of 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) for the staging of patients with esophageal 
cancer. FDG-PET has been reported to have a pooled sensi-
tivity of 67% and pooled specificity of 97% to detect distant 
lymph node and organ metastases (M stage), compared with 
pathology as the reference standard.1 A systematic review also 
found that FDG-PET has superior diagnostic performance 
compared with computed tomography (CT) for the detection 
of distant metastases in patients undergoing staging of esopha-
geal cancer, owing to its similar specificity (93% versus 91%) 
but greater sensitivity (71% versus 52%).2 There are also data 
suggesting that FDG-PET may have an impact on clinical 
management when used for preoperative staging of esopha-
geal cancer, but the magnitude of the impact is highly variable 
across studies. For instance, among patients with apparently 
resectable disease based on conventional staging (e.g., CT 
scanning of the chest and abdomen), the proportion of patients 
upstaged by PET varies fivefold across studies, from as few 
as 4.0% to as many as 23.1% of patients.3–11 Moreover, these 
studies recruited patients from university-based, tertiary or 
quaternary care centers, in which the patient population and 
patterns of care may not be broadly representative of more 
routine clinical practice. As a result, the clinical utility of 
PET/CT for staging of patients with esophageal cancer in a 
real-world setting remains unknown.
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Beginning in 2000, the government of the province of 
Ontario, Canada, implemented an evidence-based approach to 
the introduction of PET technology in which it would only 
fund PET based on high-quality evidence of its value in clini-
cal decision making. In this approach, for clinical scenarios 
where the evidentiary base suggested a potential role for PET 
but robust data were lacking, such as the use of PET for staging 
patients with potentially resectable esophageal cancer, further 
prospective data collection through a provincial field evalua-
tion (i.e., registry) was recommended.12,13 In this article, we 
present data from the Ontario PET Cancer Registry (OPCR) 
about the frequency of clinically relevant findings on PET/CT 
(e.g., upstaging of disease) when added to conventional stag-
ing for patients with potentially resectable esophageal cancer, 
and report health care utilization and outcomes after PET/CT 
as measured through linkage of OPCR data to health adminis-
trative databases, to evaluate the clinical utility of PET/CT in 
a real-world setting.
PARTICIPANTS AND METHODS
Design
We conducted a multicenter prospective cohort study 
(OPCR) of patients receiving PET/CT for staging of poten-
tially resectable esophageal cancer. Using encrypted unique 
identifiers, we linked OPCR data to provincial administrative 
databases (all housed at the Institute for Clinical Evaluative 
Sciences, Toronto, Ontario, Canada) to determine health care 
utilization and outcomes after PET/CT. The study received 
full Research Ethics Board approval from all participating 
institutions.
Study Population
The OPCR study was a multicenter (n = 6 centers) pro-
spective field evaluation funded by the Ontario Ministry of 
Health and Long-Term Care to provide access to PET for clin-
ical indications for which current evidence suggested poten-
tial benefit of PET, but for which it was deemed that further 
evidence was required to more rigorously establish its clini-
cal utility. Furthermore, as a field evaluation, the intent of the 
OPCR was to evaluate the clinical utility of PET in a real-
world setting. Therefore, referrals to the OPCR for PET scans 
were permitted from both academic and community-based 
clinicians.
Patients were eligible for inclusion in the OPCR for 
staging of esophageal cancer if they had histologically proven 
esophageal cancer that seemed to be resectable based on con-
ventional imaging (which could include endoscopic ultra-
sound). Upon providing informed consent to participate in 
the OPCR study, patients were also asked for their consent 
to anonymous linkage of their personal health information to 
provincial administrative databases for the purpose of deter-
mining patterns of health care utilization before and after PET.
In this article, we report data regarding patients receiv-
ing a first PET/CT scan for esophageal cancer staging in the 
OPCR that was performed between July 2009 and January 
2011. Records were excluded from the study cohort if they 
were for a repeat PET/CT scan for esophageal cancer.
PET/CT Imaging Procedure
The PET/CT scanners were located at six centers in 
Ontario. Machines were required to meet specified perfor-
mance criteria and to undergo quality control evaluation on 
each day imaging was performed. The PET/CT scanners were 
the following with full-ring bismuth germanate detectors: a 
Discovery ST 64 (General Electric, Waukesha, Wisconsin) in 
London, a Biograph Duo (CTI/Siemens, Knoxville, TN) at 
Princess Margaret Hospital in Toronto, a Philips Gemini Dual 
machine (Philips Electronics NV, Eindhoven, The Netherlands) 
at the Ottawa Hospital and at Sunnybrook Health Sciences 
Centre in Toronto, a Biograph 16 (Siemens, Knoxville, TN) 
at St. Joseph’s Healthcare Hamilton, and a 64 slice Gemini 
TF with lutetium-yttrium orthosilicate detectors (Philips 
Electronics NV, Eindhoven, The Netherlands) in Thunder 
Bay. To ensure consistent exam quality across all sites, stud-
ies were performed using the NEMA NU2-2001 phantom to 
verify calibration inaccuracy, verify reconstructed image reso-
lution less than 10 mm Full Width Half Maximum, and qual-
ify reconstruction methods at each site. Acquisition protocols 
were developed at each site to meet a minimum patient noise 
equivalent counts of more than 30 Mcounts/meter (+10%). 
Compliance was assured by monthly monitoring and quarterly 
review by the Quality Assurance Subcommittee.
The PET/CT examination was performed after a fast of 
6 hours; blood glucose was required to be less than 10 mmol 
per liter before intravenous administration of 18F-FDG (5 
MBq/kg, not exceeding 550 MBq). PET acquisition was pre-
ceded by a low-dose CT, and a whole-body PET/CT scan in 
supine position was obtained from the base of the skull to the 
upper half of both femurs. The examination was interpreted by 
the nuclear medicine physician with knowledge of the clinical 
history and access to correlative imaging.
Data Sources
At study entry, data were collected regarding patients’ 
age, sex, and stage (tumor, node, metastasis [T, N, and M] 
status, according to the American Joint Committee on Cancer 
[AJCC] staging manual, 6th edition).14 Nuclear medicine phy-
sicians at participating centers interpreted the PET/CT images 
and, based on these findings, recorded data regarding the N 
stage (Nx, N0, or N1) and M stage (Mx, M0, M1a, or M1b) 
of the tumor, again using the 6th edition of the AJCC staging 
manual.
To determine health care utilization before and after PET/
CT, we linked the OPCR data to provincial administrative data-
bases by using an encrypted unique identifier. The province of 
Ontario, Canada, provides its residents with universal coverage 
for hospital-based and physician services. The Ontario Health 
Insurance Plan (OHIP) Database contains data on all billing 
claims for insured physician services, surgical procedures, 
and diagnostic procedures performed across the province. 
Therefore, linkage to the OHIP Database provides the abil-
ity to comprehensively track, on a province-wide basis, health 
services received by patients enrolled in the OPCR. To charac-
terize the staging workup received by patients in the 3 months 
before PET/CT, we searched the OHIP Database for claims for 
the following procedures: CT chest (X406, X407, X125), CT 
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abdomen/pelvis (X409, X410, X126, X231, X232, X233), CT 
brain (X400, X401, X188, X402,X405, X408), magnetic reso-
nance imaging of brain (X421), nuclear medicine bone scan 
(J850, J650, J851, J651), endoscopic ultrasound (E800, E801, 
S236, S237), and neck ultrasound (J105, J405).
To track health services use after PET/CT, we searched 
the OHIP Database for claims for surgical resection of esoph-
ageal cancer (S089, S090, S123, S125, S128) and chemother-
apy (G339, G345, G359, G381). Actual radiotherapy visits are 
not reimbursed through OHIP; therefore, as a surrogate for 
radiotherapy, we searched for OHIP fee codes related to radio-
therapy planning sessions (X310, X311, X312, X313). We 
also searched for fee codes for the following palliative proce-
dures: esophageal dilation (E696, E698, Z523, Z525, Z529), 
esophageal stenting (E629, S082, S083), or laser debulking 
of tumor (E692, E695). We tracked repeat PET/CT scanning 
for esophageal cancer directly in the OPCR database. Finally, 
we determined vital status through linkage to the Registered 
Persons Database.
Outcomes
Our primary outcome was the proportion of patients 
with any clinically important change in stage based on PET/
CT findings (i.e., results that could be expected to change 
management, such as a change from apparently resectable M0 
disease before PET/CT to incurable, distant metastatic M1b 
disease based on PET/CT imaging). A detailed description of 
M stage categories,14 and the definition of clinically important 
change in stage used for this study are listed in Table 1.
We also determined, through linkage to administrative 
data, the proportion of patients receiving surgical resection, 
chemotherapy, radiotherapy, or palliative procedures at 3 and 
6 months after the index PET/CT scan, and overall survival 
through to a last follow-up date of September 1, 2011.
Analysis
We used descriptive statistics (mean and SD for continu-
ous variables and proportions for categorical variables) to sum-
marize the baseline characteristics of the study cohort (e.g., 
age, sex, time since esophageal cancer diagnosis, previous 
surgical resection, recent chemotherapy, recent radiotherapy, 
and clinical stage before PET), the results of PET/CT scan-
ning, and subsequent health care utilization.
We compared the proportion of patients receiving dif-
ferent types of treatment (surgery, chemoradiotherapy, etc.) 
according to post-PET/CT M-stage grouping by using mul-
tiple comparisons with Cochran–Armitage trend test and p 
values were adjusted by the Hommel method. We used a time-
to-event analysis to characterize overall survival of our cohort, 
following patients from the time of PET/CT to the earliest of 
either death or September 1, 2011 at which time patients were 
censored. We constructed Kaplan–Meier survival curves for 
the overall cohort, as well as stratified by pre-PET/CT M stage 
and post-PET/CT M stage, and used the log-rank test to exam-
ine for differences in survival across these strata.
RESULTS
Study Cohort
There were 504 records in the OPCR for a first PET/
CT scan for esophageal cancer staging between July 2009 
and January 2011. After excluding 13 patients who did not 
consent to data linkage, there were 491 patients in our study 
cohort, followed for a median of 336 days. The study cohort 
is described in Table 2. Patients had a mean age of 65.1 years 
(SD 10.6 years), were predominantly male (79.6%), and were 
typically staged using CT chest (91.6%) and CT abdomen/
pelvis (91.0%). On the basis of pre-PET clinical assessment 
and conventional imaging, the substantial majority of patients 
(93.5%) had apparently resectable disease (i.e., M0 disease) at 
the time of enrollment.
Change in Stage after PET/CT
PET/CT imaging led to clinically important changes in 
stage for a total of 118 of 491 patients (24.0%): 107 patients 
(21.8%) were upstaged by PET/CT results (i.e., from M0 to 
M1a or M1b; or from M1a to M1b), and 11 patients (2.2%) 
were downstaged by PET/CT results (from M1b to M0; or 
from M1a to M0). There were 74 patients (15.1%) who were 
upstaged to M1b status based on results of PET/CT (Table 3).
TABLE 1.  M Stage Categories and Definition of Clinically Important Change in Stage
M stage category Description
  M0 No distant metastasis (curable)
  M1a Metastasis in nonregional lymph nodes, i.e., cervical or celiac nodes 
(potentially curable)
  M1b Distant metastasis, i.e., metastasis in distant lymph nodes or other distant 
sites such as lung or liver (incurable)
Clinically important change in stage (primary outcome) defined as any of: Stage before PET/CT Stage based on PET/CT
  Upstaged to incurable status M0 or M1a M1b
  Upstaged to potentially incurable status M0 M1a
  Downstaged to curable status M1b or M1a M0
  Downstaged to potentially curable status M1b M1a
M stage definitions are based on the American Joint Committee on Cancer staging manual, 6th edition.14
PET, positron emission tomography; CT, computed tomography.
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Health Care Utilization and 
Outcomes after PET/CT
By 6 months after PET/CT, the majority of the study 
cohort had undergone some form of specific therapy for their 
esophageal cancer, most commonly surgical resection with or 
without adjunctive therapy (44.4%) or combination chemora-
diotherapy (25.1%; Table 4). Patterns of care at 6 months after 
PET/CT differed depending on the imaging findings on PET/CT, 
with greater use of surgical resection with or without adjunctive 
therapy in patients with M0 disease (54.4%) than those with 
M1a (25.0%; p < 0.001) or M1b (7.3%; p < 0.001) disease, and 
greater use of combination chemoradiotherapy in patients with 
M1b disease (43.9%) than those with M1a (22.2%; p = 0.002) 
or M0 (21.2%; p < 0.001) disease. Use of palliative procedures 
(esophageal dilatation or esophageal stenting) was similar in 
patients with M0 (30.8%), M1a (22.2%), and M1b (29.3%) dis-
ease (p = 0.65). Health care utilization at 3 months is shown in 
Supplemental Table 1 (Supplemental Digital Content 1, http://
links.lww.com/JTO/A502).
During follow-up, 10 patients (2.0%) and 22 patients 
(4.5%) had received a repeat PET/CT scan for esophageal 
cancer at 3 months and 6 months, respectively; all patients 
who received repeat PET/CT scans for esophageal cancer 
staging had M0 disease on their index PET/CT scan.
Overall survival for the entire study cohort (median sur-
vival, 603 days), is shown in Figure 1A. Survival decreased 
significantly with higher M stage based on conventional (pre-
PET/CT) staging (median survival for M0, 628 days; M1a, 
319 days; M1b, 217 days; p = 0.007; Fig. 1B) and these dif-
ferences became more pronounced based on reclassified stage 
after PET/CT (median survival for M0, 701 days; M1b, 227 
days; p < 0.001; Fig. 1C; note: median survival could not be 
calculated for patients with stage M1a disease on PET/CT 
because more than 50% of the patients were still alive at maxi-
mum follow-up).
DISCUSSION
This prospective, multicenter field evaluation of patients 
with potentially resectable esophageal cancer found that PET/
CT led to clinically important changes in stage for one in 
every four patients scanned. In most cases this was because 
of upstaging of disease to an incurable (M1b) status and 
these patients had lower rates of esophageal resection during 
follow-up.
Strengths of our study include its prospective, multi-
center design, and size. To our knowledge, it is the largest pub-
lished experience with PET/CT for staging of patients with 
potentially resectable esophageal cancer. More importantly, 
previous studies have enrolled patients from highly special-
ized, university-based centers.3–11 Our study is, to our knowl-
edge, the first to confirm the clinical utility of PET/CT when 
used in a real-world setting.
Our study also has limitations. First, our data are based 
on the 6th edition of the AJCC staging system, because this 
was the system in use at the time our study was conducted.14 
It is likely that fewer patients in our cohort would have been 
upstaged by PET/CT had the current 7th edition been used 
instead. This is because nodes considered as nonregional 
lymph node metastases and classified as M1a under the 6th 
edition are now classified as M0 under the 7th edition.15 
Therefore, patients in our study who were M0 based on con-
ventional imaging and upstaged because of findings of M1a 
TABLE 3.  Change in Staging of Esophageal Cancer after 
PET/CT
Post-PET M Stage
M0 (N = 373) M1a (N = 36) M1b (N = 82)
Pre-PET M Stage
M0 362 33 64
M1a 10 3 10
M1b 1 0 8
M stage definitions are based on the American Joint Committee on Cancer staging 
manual, 6th edition.
PET, positron emission tomography; M0, no distant metastasis; M1a, metastasis in 
regional lymph nodes; M1b, distant metastasis; CT, computed tomography.
TABLE 2.  Characteristics of Study Cohort
PET/CT for Staging of  
Potentially Curable 
Esophageal Cancer (N = 491)
Age, yr (mean ± SD) 65.1 ± 10.6
Sex
  Male 391 (79.6)
  Female 100 (20.4)
Diagnostic imaging 6 weeks  
before PET/CT
  CT chest 391 (79.6)
  CT abdomen/pelvis 385 (78.4)
  CT or MRI brain 145 (29.5)
  Nuclear medicine bone scan 52 (10.6)
  Endoscopic ultrasound 25 (5.1)
  Neck ultrasound 10 (2.0)
TNM stage before PET/CT
  Stage 0 (Tis, N0, M0) 9 (1.8)
  Stage I (T1, N0, M0) 82 (16.7)
  Stage IIA (T2/3, N0, M0) 127 (25.9)
  Stage IIB (T1/2, N1, M0) 62 (12.6)
  Stage III (T3, N1, M0; T4, any N, M0) 84 (17.1)
  Stage IVA (any T, any N, M1a) 23 (4.7)
  Stage IVB (any T, any N, M1b) 9 (1.8)
M stage before PET/CTa
  M0 459 (93.5)
  M1a 23 (4.7)
  M1b 9 (1.8)
Chemotherapy in past year 36 (7.3)
Radiotherapy in past year 60 (12.2)
All data are number (percent) unless otherwise stated. TNM stage based on the 
American Joint Committee on Cancer staging manual, 6th edition.14
a M0, no distant metastasis; M1a, metastasis in regional lymph nodes; M1b, distant 
metastasis.
PET/CT, positron emission tomography/computed tomography; MRI, magnetic 
resonance imaging; TNM, tumor, node, metastasis.
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disease on PET/CT would not have been upstaged according 
to the 7th edition. Reclassification of data in Table 3 suggests 
that 15.1% of patients (74 of 491) in our study (approximately 
1 in every 7 patients) would have been upstaged by PET/CT to 
M1 status under the 7th edition, which still represents a clini-
cally important impact of PET/CT, given that patients found 
to have M1 disease would no longer be candidates for curative 
surgical resection. Second, we did not have access to the results 
of biopsies that may have been performed to further evaluate 
FDG-avid lesions detected on PET/CT, and recognize that this 
is an important limitation of our study. However, it is reassur-
ing to note that prior studies have reported that FDG-PET has 
high specificity (i.e., >90%) for the detection of distant metas-
tases,1,2 and a low false-positive rate of 3.7%.10 Nonetheless, 
it remains unknown whether some patients in our cohort may 
have had false-positive results on PET/CT and may have had 
potentially life-saving therapy incorrectly withheld as a result. 
Third, our study did not include a control group of otherwise 
similar patients who did not undergo PET/CT. Therefore, our 
findings do not permit a direct assessment of the magnitude of 
the impact of PET/CT on clinical decision making. However, 
our observation that the rates of surgical resection were much 
higher among patients with M0 status on PET/CT compared 
with those with M1b status on PET/CT does suggest that 
PET/CT had an important influence on subsequent manage-
ment by avoiding futile, aggressive interventions in patients 
with incurable metastatic disease.
We found that PET/CT stage was associated with dif-
ferent patterns in subsequent management, whereby patients 
with no evidence of metastatic disease on PET/CT were 
more likely to undergo surgical resection. Although most 
patients (54%) in our cohort with M0 disease based on PET/
CT staging underwent esophagectomy, some patients did not. 
However, the rate of surgical resection we observed is simi-
lar to rates of 46% and 30% seen in other population-based 
cohorts of localized esophageal cancer in the United States 
and Australia, respectively.16,17 Reasons for the nonsurgical 
management (e.g., with definitive chemoradiotherapy)18,19 of 
patients with M0 disease in our cohort may have included 
poor performance status, high perioperative risk, or patient 
preferences.
Our finding that 15.1% of patients were upstaged to 
M1b status after PET/CT is broadly consistent with other 
studies that have examined this issue (range, 4.0%–23.1%).3–11 
In particular, the rate of upstaging in our study is consistent 
with data from the prospective, multicenter American College 
of Surgeons Oncology Group trial, in which the proportion 
of patients upstaged to M1b status was 4.8%, but as high as 
14.3% when patients with a positive PET scan were classi-
fied as upstaged if no biopsy was done but confirmatory imag-
ing was positive.10 However, the reclassification rate in our 
study is higher than the rate of upstaging (4.0%) observed in a 
recent prospective study conducted by van Westreenen et al.11 
at three centers in The Netherlands. It is possible that some 
physicians occasionally underreported or underestimated 
patients’ actual stage at entry into our study (e.g., patients 
may have been labeled as having M0 disease, but with CT 
imaging showing lesions consistent with metastatic disease), 
which would have allowed patients to access PET through the 
provincial registry study; however, we have no evidence to 
support this assertion. A more plausible explanation for the 
lower rate of upstaging in the study by van Westreenen et al. 
likely relates to the more intensive, protocolized, multimodal-
ity nature (including endoscopic ultrasound) of the pre-PET 
diagnostic staging used at that academic center. In contrast, 
our field evaluation was conducted in a jurisdiction where 
endoscopic ultrasound was not widely available and consisted 
of a more general, population-based sample of patients who 
were thought to have potentially resectable esophageal cancer 
based on conventional real-world staging. Therefore, our data 
TABLE 4.  Health Services Use during the 6 Months after PET/CT
Post-PET M Stagea
All Patients (N = 491)M0 (N = 373) M1a (N = 36) M1b (N = 82)
Cancer-specific treatment
  Surgery + chemotherapy + radiotherapy 92 (24.7) 7 (19.4) 3 (3.7) 102 (20.8)
  Surgery + chemotherapy 44 (11.8) 2 (5.6) 1 (1.2) 47 (9.6)
  Surgery + radiotherapy 5 (1.3) 0 (0.0) 0 (0.0) 5 (1.0)
  Surgery only 62 (16.6) 0 (0.0) 2 (2.4) 64 (13.0)
  Chemotherapy + radiotherapy 79 (21.2) 8 (22.2) 36 (43.9) 123 (25.1)
  Chemotherapy only 9 (2.4) 7 (19.4) 12 (14.6) 28 (5.7)
  Radiotherapy only 47 (12.6) 7 (19.4) 14 (17.1) 68 (13.8)
  No treatment 35 (9.4) 5 (13.9) 14 (17.1) 54 (11.0)
Palliative treatment
  Esophageal dilation 100 (26.8) 5 (13.9) 18 (22.0) 123 (25.1)
  Esophageal stenting 31 (8.3) 4 (11.1) 10 (12.2) 45 (9.2)
  Laser debulking of tumor 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Any of the above palliative procedures 115 (30.8) 8 (22.2) 24 (29.3) 147 (29.9)
aM stage definitions are based on the American Joint Committee on Cancer staging manual, 6th edition.
PET, positron emission tomography; CT, computed tomography.
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FIGURE 1.  Kaplan–Meier survival curves for 
the overall study cohort (A); study cohort strat-
ified by pre-PET M stage, p = 0.007 (log-rank 
test) (B); and study cohort stratified by M stage 
based on PET/CT imaging, p < 0.001 (log-rank 
rest) (C). M stage definitions are based on the 
American Joint Committee on Cancer staging 
manual, 6th edition. PET, positron emission 
tomography; CT, computed tomography; 
M0, no distant metastasis; M1a, metastasis in 
regional lymph nodes; M1b, distant metastasis.
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provide an assessment of the impact of PET/CT when used for 
the staging of patients with potentially resectable esophageal 
cancer in a general population setting.
In conclusion, we found that PET/CT led to clinically 
important changes in stage for an appreciable number of 
patients with potentially resectable esophageal cancer (i.e., a 
number needed to scan of 4). In particular, PET/CT can upstage 
patients with apparently resectable disease based on conven-
tional staging, can prevent patients with incurable disease from 
receiving futile, aggressive interventions, and can contribute 
importantly to the clinical management of these patients.
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